The relationship between osteopontin and adiponectin in patients with essential hypertension

Clinical and Experimental Hypertension

Volumn 32, Issue 6, 2010, Pages 358-363

  Kurata, Mie ^a   Okura, Takafumi ^a   Irita, Jun ^a   Enomoto, Daijiro ^a   Nagao, Tomoaki ^a   Jotoku, Masanori ^a   Miyoshi, Ken Ichi ^a   Higaki, Jitsuo ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Adiponectin; C reactive protein (CRP); Inflammation; Osteopontin (OPN); Renin angiotensin aldosterone system (RAAS)

Indexed keywords

ADIPONECTIN; ALDOSTERONE; C REACTIVE PROTEIN; CREATININE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OSTEOPONTIN; TRIACYLGLYCEROL;

AGED; ALDOSTERONE BLOOD LEVEL; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CHOLESTEROL BLOOD LEVEL; CORRELATION COEFFICIENT; CREATININE BLOOD LEVEL; ESSENTIAL HYPERTENSION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; REGRESSION ANALYSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE;

ADIPONECTIN; AGED; ALDOSTERONE; C-REACTIVE PROTEIN; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; OSTEOPONTIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 78049442925     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.3109/10641961003628494     Document Type: Article

References (37)

1. Giachelli CM, Bae N, Almeida M, Denhardt DT, Alpers CE, Schwartz SM. Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J Clin Invest 1993;92:1686-1696.
2. Liaw L, Almeida M, Hart CE, Schwartz SM, Giachelli CM. Osteopontin promotes vascular cell adhesion and spreading and is chemotactic for smooth muscle cells in vitro. Circ Res 1994;74:214-224.
3. Liaw L, Lindner V, Schwartz SM, Chambers AF, Giachelli CM. Osteopontin and beta 3 integrin are coordinately expressed in regenerating endothelium in vivo and stimulate Arg-Gly-Asp-dependent endothelial migration in vitro. Circ Res 1995;77:665-672.
4. Liaw L, Skinner MP, Raines EW, Ross R, Cheresh DA, Schwartz SM, Giachelli CM. The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. Role of alpha v beta 3 in smooth muscle cell migration to osteopontin vitro. J Clin Invest 1995;95:713-724.
5. Scatena M, Almeida M, Chaisson ML, Fausto N, Nicosia RF, Giachelli CM. NF-kappaB mediates alphavbeta3 inte-grin-induced endothelial cell survival. J Cell Biol 1998; 141: 1083-1093.
6. Weintraub AS, Giachelli CM, Krauss RS, Almeida M, Taub-man MB. Autocrine secretion of osteopontin by vascular smooth cells regulates their adhesion to collagen gets. Am J Pathol 1996;149:259-272.
7. Campos AH, Zhao Y, Pollman MJ, Gibbons GH. DNA microarray profiling to identify angiotensin-responsive genes in vascular smooth muscle cells: potential mediators of vascular disease. Circ Res 2003;92:111-118.
8. Irita J, Okura T, Kurata M, Miyoshi K, Fukuoka T, Higaki J. Osteopontin in rat renal fibroblasts: Functional properties and transcriptional regulation by aldosterone. Hyper-tension 2008;51:507-513.
9. Bruemmer D, Collins AR, Noh G, Wang W, Territo M, Arias-Magallona S, Fishbein MC, Blaschke F, Kintscher U, Graf K, Law RE, Hsueh WA. AngiotensinII-accelerated atherosclerosis and aneurysm formation in attenuated in osteopontin-defi-cient mice. J Clin Invest 2003;112:1318-1331.
10. Ohmori R, Momiyama Y, Taniguchi H, Takahashi R, Kusuhara M, Nakamura H, Ohsuzu F. Plasma osteopontin levels are associated with the presence and extent of coronary artery disease. Atherosclerosis 2003;170:333-337.
11. Kurata M, Okura T, Watanabe S, Fukuoka T, Higaki J. Osteopontin and carotid atherosclerosis in patients with essen tial hypertension. Clin Sci 2006;111:319-324.
12. Minoretti P, Falcone C, Calcagnino M, Emanuele E, Buzzi MP, Coen E, Geroldi D. Prognostic significance of plasma osteopontin levels in patients with chronic stable angina. Eur Heart J 2006;27:802-807.
13. Irita J, Okura T, Manabe S, Kurata M, Miyoshi K, Watanabe S, Fukuoka T, Higaki J. Plasma osteopontin levels are higher in patients with primary aldosteronism than in patients with essential hypertension. Am J Hypertens 2006;19:293-297.
14. Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ Res 2005;96:939-949.
15. Kadowaki T, Hara K, Yamauchi T, Terauchi Y, Tobe K, Nagai R. Molecular mechanism of insulin resistance and obesity. Exp Biol Med 2003;228:1111-1117.
16. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adipo-nectin receptors in insulin resistance, diabetes, and the metabolic syndorome. J Clin Invest 2006;116:1784-1792.
17. Haluzik M, Parizkova J, Haluzik MM. Adiponectin and its role in the obesity-induced insulin resistance and related complications. Physiol Res 2004;53:123-129.
18. Ochi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, Hotta K, Nishida M, Takahashi M, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y. Novel modulator for endothelial adhesion molecules: Adipocyte-derived plasma protein adi-ponectin. Circulation 1999;100:2473-2476.
19. Ochi N, Kihara S, Arita Y, Nishida M, Matsuyama A, Okamoto Y, Ishigami M, Kuriyama H, Kishida K, Nishizawa H, Hotta K, Muraguchi M, Ohmoto Y, Yamashita S, Funahashi T, Matsuzawa Y. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001;103:1057-1063.
20. Sharma AM, Janke J, Gorzelniak K, Engeli S, Luft FC. Angio-tensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension 2002;40:609-611.
21. Guo C, Ricchiuti V, Lian BQ, Yao TM, Coutinho P, Romero JR, Li J, Williams GH, Adler GK. Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines. Circulation 2008;117:2253-2261.
22. Fallo F, Della Mea P, Sonino N, Bertello C, Ermani M, Vettor R, Veglio F, Mulatero P. Adiponectin and insulin sensitivity in primary aldosteronism. Am J Hypertens 2007; 20: 855-861.
23. Blaschke F, Bruemmer D, Yin F, Takata Y, Wang W, Fishbein MC, Okura T, Higaki J, Graf K, Fleck E, Hsueh WA, Law RE. C-reactive protein induces apoptosis in human coronary vascular smooth muscle cells. Circulation 2004;110: 579-587.
24. Pasceri V, Cheng JS, Willerson JT, Yeh ET. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001;103:2531-2534.
25. Peng N, Liu JT, Gao DF, Lin R, Li R. AngiotensinII-induced C-reactive protein generation: Inflammatory role of vascular smooth muscle cells in atherosclerosis. Atherosclerosis 2007;193:292-298.
26. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-1695.
27. Morishita R, Gibbons GH, Tomita N, Zhang L, Kaneda Y, Ogihara T, Dzau VJ. Antisense oligodeoxynucleotide inhibition of vascular angiotensin-converting enzyme expression attenuates neointimal formation: Evidence for tissue angio-tensin-converting enzyme function. Arterioscler Thromb Vasc Biol 2000;20:915-922.
28. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998;338:645-652.
29. Montezano AC, Callera GE, Yogi A, He Y, Tostes RC, He G, Schiffrin EL, Touyz RM. Aldosterone and Angiotensin II Syn-ergistically Stimulate migration in vascular smooth muscle cells through c-Src-regulated redox-sensitive RhoA pathways. Arterioscler Thromb Vasc Biol 2008;28:1511-1518.
30. Tanaka N, Momiyama Y, Ohmori R, Yonemura A, Ayaori M, Ogura M, Sawada S, Kusuhara M, Nakamura H, Ohsuzu F. Effect of atorvastation on plasma osteopontin levels in patients with hypercholesterolemia. Arterioscler Thromb Vasc Biol 2006; 26:e129-e130.
31. Shanahan CM, Cary NR, Metcalfe JC, Weissberg PL. High expression of genes for calcification-regulating protein in human atherosclerotic plaques. J Clin Invest 1994; 93: 2393-2402.
32. Giachelli CM, Bae N, Almeida M, Denhardt DT, Alpers CE, Schwartz SM. Osteopontin is elevated during neoint-ima formation in rat arteries and in a novel comoponent of human atherosclerotic plaques. J Clin Invest 1993;92: 1686-1696.
33. Ikead T, Shirasawa T, Esaki Y, Yoshiki S, Hirokawa K. Osteopontin mRNA is expressed by smooth muscle-derived foam cells in human athesosclerosis lesions of the aorta. J Clin-vest 1993;92:2814-2820.
34. Montero I, Orbe J, Varo N, Beloqui O, Monreal JI, Rodriguez JA, Diez J, Libby P, Paramo JA. C-reactive protein induces matrix metalloproteinase-1 and-10 in huma endothelial cells: Implications for clinical and subclinical atherosclerosis. J Am Coll Cardiol 2006;47:1369-1378.
35. Krupinski J, Turu MM, Martinez-Gonzalaez J, Carvajal A, Juan-Babot JO, Iborra E, Slevin M, Rubio F, Badimon L. Endogenous expression of C-reactive protein is increased in active (ulcerated noncomplicated) human carotid artery plaques. Stroke 2006; 37:1200-1204.
36. Watanabe S, Okura T, Kurata M, Irita J, Manabe S, Miyoshi K, Fukuoka T, Murakami K, Higaki J. The effect of losartan and amlodipine on serum adiponectin in Japanese adults with essential hypertension. Clin Ther 2006;28:1677-1685.
37. Gavrila A, Peng CK, Chan JL, Mietus JE, Goldberger AL, Mantzoros CS. Diurnal and ultradian dynamics of serum adi-ponectin in healthy men: Comparison with leptin, circulating soluble leptin receptor, and cortisol patterns. J Clin Endocrinol Metab 2003;88:2838-2843